About Us

Learn about who we are, what we believe
and the people who lead us

Our Story Serving patient needs is our passion; delivering revolutionary treatments is our mission Our Leadership Our experienced leaders are bound by passion and science Our Values We live our values of commitment, empowerment and teamwork Our Responsibility Advancing a vision for change Medical Affairs We are committed to advancing science and medicine through awareness, education and research

Our Focus

Discover our unique scientific approach
for diseases with high unmet need.

Demodex Blepharitis Highly prevalent and damaging eyelid disease Lyme Disease A growing public health crisis with no approved solution Meibomian Gland Disease Often associated with <em>Demodex</em> infestation Rosacea A common inflammatory skin condition

Our Therapies

The first and only FDA-approved
treatment for Demodex blepharitis

XDEMVY® (lotilaner ophthalmic solution) 0.25% Available to prescribe today

Our Pipeline

Explore the possibilities of our robust pipeline
to address significant unmet patient needs

Pipeline Overview A commitment to pursuing the root cause of disease TP-03 A potential candidate for meibomian gland disease TP-04 An investigational treatment for papulopustular rosacea TP-05 An investigational therapy for the prevention of Lyme disease

Investors & News

Find additional corporate
and stock information.

Investors Overview

News & Presentations

Publications Corporate Governance

Stock Information

Other Resources

Our Story Our Leadership Our Values Our Responsibility Medical Affairs

Demodex Blepharitis Lyme Disease Meibomian Gland Disease Rosacea

XDEMVY® (lotilaner ophthalmic solution) 0.25%

Pipeline Overview TP-03 TP-04 TP-05

Careers

Financials

SEC Filings

Filing date	Form	Description	View
Feb 14, 2022	SC 13G/A	An amendment to the SC 13G filing	0000929638-22-000471.pdf 0000929638-22-000471.rtf 0000929638-22-000471.xls View HTML
Feb 14, 2022	SC 13G/A	An amendment to the SC 13G filing	0001193125-22-041979.pdf 0001193125-22-041979.rtf 0001193125-22-041979.xls View HTML
Feb 14, 2022	SC 13G/A	An amendment to the SC 13G filing	0001193125-22-041990.pdf 0001193125-22-041990.rtf 0001193125-22-041990.xls View HTML
Feb 14, 2022	SC 13G/A	An amendment to the SC 13G filing	0001193125-22-042273.pdf 0001193125-22-042273.rtf 0001193125-22-042273.xls View HTML
Feb 11, 2022	SC 13G/A	An amendment to the SC 13G filing	0001213900-22-007082.pdf 0001213900-22-007082.rtf 0001213900-22-007082.xls View HTML
Feb 3, 2022	3	Initial filing by director officer or owner of more than ten percent.	0001661539-22-000004.pdf 0001661539-22-000004.rtf 0001661539-22-000004.xls View HTML
Feb 3, 2022	4	Statement of changes in beneficial ownership of securities	0001661539-22-000005.pdf 0001661539-22-000005.rtf 0001661539-22-000005.xls View HTML
Feb 2, 2022	8-K	Report of unscheduled material events or corporate event	0001819790-22-000004.pdf 0001819790-22-000004.rtf 0001819790-22-000004.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
Jan 28, 2022	SC 13G/A	An amendment to the SC 13G filing	0001193125-22-021382.pdf 0001193125-22-021382.rtf 0001193125-22-021382.xls View HTML
Jan 4, 2022	8-K	Report of unscheduled material events or corporate event	0001819790-22-000002.pdf 0001819790-22-000002.rtf 0001819790-22-000002.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML

Anchor Link for Quarterly Results

Data provided by Kaleidoscope.